ATHE

Alterity Therapeutics Limited NASDAQ Listed Sep 29, 2003

Healthcare ·Biotechnology ·AU · alteritytherapeutics.com

$4.67

Mkt Cap $42.3M

52w Low $2.66 46.3% of range 52w High $7.00

50d MA $3.83 200d MA $4.03

P/E (TTM) -4.1x

EV/EBITDA -2.3x

P/B 1.2x

Debt/Equity 0.0x

ROE —

P/FCF -5.8x

RSI (14) —

ATR (14) —

Beta -0.07

50d MA $3.83

200d MA $4.03

Avg Volume 14.2K

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

SIC Code

2834

CIK (SEC)

1131343

Phone

61 3 9349 4906

460 Bourke Street · Melbourne, VIC 3000 · AU

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Feb 25, 2026	AMC	-0.23	-0.38	-65.9%	3.43	-0.9%	+2.9%	-2.5%	+0.3%	-1.4%	+0.0%	—
Aug 28, 2025	AMC	-0.43	-0.40	+7.2%	5.02	+3.4%	-1.6%	+4.5%	-1.7%	+0.0%	+0.0%	—
Feb 28, 2025	AMC	-0.53	-0.00	+99.9%	3.78	+1.1%	-3.7%	-2.2%	+2.2%	-1.9%	+4.2%	—
Feb 3, 2025	AMC	—	-0.00	—	4.99	+2.2%	-9.6%	-5.8%	+0.0%	+0.0%	+8.7%	—
Aug 29, 2024	AMC	-0.05	-0.00	+96.2%	1.51	-0.7%	-1.3%	-7.4%	+0.7%	-9.4%	-1.6%	—
Apr 11, 2024	AMC	—	-0.00	—	2.63	+7.6%	+11.8%	-16.7%	-16.3%	-2.0%	+6.5%	—
Feb 28, 2024	AMC	-0.11	-0.00	+97.5%	1.91	+0.0%	-2.1%	-7.5%	+0.0%	+1.2%	-2.3%	—
Jan 30, 2024	AMC	—	-0.00	—	2.27	+1.8%	-7.0%	+0.9%	-2.3%	-1.4%	-4.9%	—
Jun 30, 2023	AMC	—	-0.00	—	2.79	-1.4%	-3.9%	+3.4%	+2.9%	-2.5%	-0.4%	—
Mar 31, 2023	AMC	-0.12	-0.00	+99.0%	2.78	-3.6%	-1.1%	+1.8%	+0.7%	-0.4%	+0.4%	—
Feb 28, 2023	AMC	-1.81	-1.11	+38.6%	3.21	-0.9%	+2.8%	-4.2%	-1.6%	+2.6%	+1.9%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Jan 30	Maxim Group	Maintains	Buy → Buy	—	$2.91	$5.75	+97.6%	+57.0%	+5.0%	+4.0%	-9.6%	-5.8%
Mar 7	Benchmark	Maintains	Speculative Buy → Speculative Buy	—	$1.71	$1.68	-1.8%	-2.9%	+3.0%	+0.0%	-2.9%	+12.7%
Jun 5	Ladenburg Thalmann	Maintains	Buy → Buy	—	$2.85	$2.91	+2.1%	+1.8%	-3.1%	+2.5%	+0.3%	-0.3%
Aug 3	Ladenburg Thalmann	Maintains	Buy → Buy	—	$6.00	$6.30	+5.0%	+6.7%	+4.7%	-6.0%	+1.6%	-3.1%
Jun 23	Goldman Sachs	Maintains	Neutral → Neutral	—	$6.10	$6.10	+0.0%	+4.9%	-1.6%	+3.2%	+0.0%	-1.5%
Aug 20	Benchmark	Maintains	Speculative Buy → Buy	—	$12.80	$13.10	+2.3%	+3.9%	+2.3%	-1.5%	+2.2%	-1.5%
Jan 5	B. Riley FBR	Maintains	Buy → Buy	—	$31.70	$31.50	-0.6%	+2.5%	-4.0%	-7.4%	-0.7%	+5.2%
Mar 31	H.C. Wainwright	Downgrade	Buy → Neutral	—	$591.60	$180.60	-69.5%	-71.6%	-17.9%	+0.4%	+4.8%	-4.1%
Mar 31	MLV & Co.	Downgrade	Buy → Hold	—	$591.60	$180.60	-69.5%	-71.6%	-17.9%	+0.4%	+4.8%	-4.1%
Feb 26	H.C. Wainwright	Maintains	Buy → Buy	—	$561.60	$621.60	+10.7%	+20.0%	+2.7%	-1.9%	-4.3%	+1.8%
Feb 18	H.C. Wainwright	Maintains	Buy → Buy	—	$435.00	$498.60	+14.6%	+39.3%	-13.3%	-7.9%	-0.5%	+12.5%
Dec 20	Burrill & Company	Maintains	Market Perform → Perform	—	$130.80	$138.00	+5.5%	+1.8%	-4.1%	+1.9%	+0.0%	-0.5%

Data updated apr 26, 2026 9:41am · Source: massive.com